Ipsen and Sutro Biopharma sign an exclusive global licensing deal for STRO-003, an ADC targeting ROR1 tumor antigen.

Ipsen and Sutro Biopharma sign an exclusive global licensing deal for STRO-003, a next-gen ADC targeting ROR1 tumor antigen. In pre-clinical final stages, STRO-003 leverages Sutro's technology for a stable conjugate with exatecan payloads. Ipsen assumes responsibility for Phase I, IND submission, and all subsequent activities, with Sutro eligible for up to $900M in milestone payments.